Holger W. Hirte - Concepedia

Author

Holger W. Hirte

McMaster University

Also Known As

H Hirte, H W Hirte, H. HIRTE, H. Hirte, H. W. Hirte, H.W. Hirte, Holger Hirte, Holger W Hirte, Holger W. Hirte

Publications

Citations

H-Index

Concepts

All Affiliations

McMaster University Princess Margaret Cancer Centre Hamilton Regional Laboratory Medicine Program Juravinski Cancer Centre BC Cancer Agency

About

Holger W. Hirte is an author at McMaster University specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	22	3.5K
2	Health Sciences	3	3	149
3	Engineering	1	1	15
4	Natural Sciences	1	1	21
5	Allergy	1	1	68

Holger W. Hirte

Publications

4.4K

Citations

H-Index

Page 1

	Year	Citations
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, The Lancet Oncology MedicineRandomised Phase 2GynecologyCancer TreatmentOncology	2014	540
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors Malcolm J. Moore, Holger W. Hirte, Lillian L. Siu, Annals of Oncology MedicinePharmacologyDays On/7 DaysNovel Raf KinaseRefractory Solid Tumors	2005	301
Doxycycline decreases tumor burden in a bone metastasis model of human breast cancer. Wilhelmina Duivenvoorden, Snežana Popović, Šárka Lhoták, PubMed Breast OncologyTetracycline FamilyPathologyHuman Breast CancerMetronomic Chemotherapy	2002	123
Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas Anastasios Stathis, Sébastien J. Hotte, Eric X. Chen, Clinical Cancer Research Lymphoid NeoplasiaTherapeutic Drug MonitoringOncologyMedicineClinical Trials	2011	99
Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells Wilhelmina Duivenvoorden, Holger W. Hirte, Gurmit Singh Clinical & Experimental Metastasis	1999	99
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors Ignacio Durán, Sébastien J. Hotte, Holger W. Hirte, Clinical Cancer Research	2007	97
Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells. Wilhelmina Duivenvoorden, Holger W. Hirte, Gurmit Singh PubMed Tumor BiologyOncologyMatrix Metalloproteinase ActivityMedicineMetalloprotein	1997	89
Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221 Anna V. Tinker, Holger W. Hirte, Diane Provencher, Clinical Cancer Research	2019	88

Page 1